The protocol for our ongoing Pivotal Study for the aXess hemodialysis graft has been published in the Journal of Vascular Access, and can be accessed here: https://pubmed.ncbi.nlm.nih.gov/37165650/. The Pivotal Study is a prospective, single-arm, multicenter clinical study to assess [...]
aXess, Xeltis’ restorative vascular access graft for hemodialysis, has been successfully implanted in the first patient in Greece, as part of the aXess pivotal trial. The procedure took place at the University Hospital of Patras, which recently started enrolling [...]
aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to standard hemodialysis access treatment EINDHOVEN, The Netherlands – 28 April 2023, Xeltis, a developer of transformative implants that enable [...]
New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing from the LSP Health Economics Fund 2, in series D2 fundraise Use of proceeds to advance Xeltis’ aXess vascular [...]
If joining a truly innovative medtech company may be part of your end-of-year resolutions, we have good news for you: Xeltis is hiring! We are expanding our device development and clinical trial programs and scaling up our R&D, Clinical [...]
The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh, at the Polymers in Medicine and Biology Workshop, Napa (CA - USA) on Wednesday 30 November. The favourable outcomes included [...]
Professor Frans Moll, University Medical Center Utrecht, will update an audience of international vascular surgeons at the VEITH Symposium in New York City this Saturday. In a session on new technologies for vascular access creation, Professor Moll will provide [...]
Dr An de Vriese, who is playing a leading role in the ongoing European pivotal trial investigating the aXess vascular graft, discussed the study and the significant potential held by Xeltis’ technology in dialysis access care in Renal Interventions. [...]
Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have been successfully implanted, as part of the AXESS European pivotal trial at AZ Sint-Jan Brugge-Oostende AV in Bruges, Belgium [...]
Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device, potentially superior to saphenous veins. It is the most prolonged patency ever demonstrated for a small-diameter (4mm diameter; 15cm [...]
